Epocrates (EPOC) Shareholder Buyout Summary


Epocrates (EPOC) Shareholder Buyout Summary

On January 7, 2012, Epocrates announced that it had agreed to be acquired by athenahealth, Inc.. The transaction values Epocrates at approximately $293 million or $11.75 per share.

Is this a fair merger for Epocrates (EPOC) shareholders?

Published reports indicate that at least one analyst has set a price target of $15 for EPOC common shares. A basic question then is whether $11.75 is a fair price per share?

Has the board of directors of Epocrates exercised its fiduciary duties to EPOC shareholders?

Epocrates (EPOC) Buyout Shareholder Investigation

We are investigating whether the proposed transaction is fair to Epocrates shareholders.  The investigation concerns whether the EPOC board of directors’ process for consideration of the proposed transaction was adequate, whether Epocrates is acting in its shareholders’ best interests and whether the proposed share price to be paid to Epocrates shareholders is fair and adequate. 
If you own the common stock of Epocrates and if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please fill out the contact form on this web page or call Attorney George Pressly at Morgan & Morgan toll free at 1 (800) 631-6234.

Entity Name: 
Epocrates, Inc.
Stock Symbol: 

EPOC Shareholder Submission Form

Take Action!